SCHEMBL5544407

SCHEMBL5544407

CN(C)c1ccc(NC(=O)N2CCC3(CC2)Cn2cc([N+](=O)[O-])nc2O3)cc1

nearest known ligand 0.47

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
GAA P10253 2/20 0.47
KMT2A Q03164 2/20 0.47
MEN1 O00255 1/20 0.47
TP53 P04637 1/20 0.47
SMN1; SMN2 Q16637 1/20 0.47
ESR2 Q92731 1/20 0.47
MAPT P10636 2/20 0.39
KDM4E B2RXH2 1/20 0.39
CNR2 P34972 1/20 0.38
KIT P10721 1/20 0.37
ALDH1A1 P00352 1/20 0.37
MAPK1 P28482 1/20 0.37
TRPM8 Q7Z2W7 3/20 0.36
KCNH2 Q12809 4/20 0.36
NAMPT P43490 1/20 0.36
DGAT1 O75907 1/20 0.36
MCL1 Q07820 1/20 0.36
BAZ1A Q9NRL2 1/20 0.35
LMNA P02545 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5537221 0.88 TRPM8 (0.48) GAAKMT2AMEN1ALDH1A1TRPM8
SCHEMBL5543599 0.87 TRPM8 (0.39) GAAKMT2AMEN1ALDH1A1TRPM8
SCHEMBL5541336 0.84 KCNH2 (0.39) GAAKMT2ASMN1; SMN2MAPTKDM4E
SCHEMBL5546023 0.79 KCNH2 (0.41) KMT2AMEN1MAPTALDH1A1MAPK1
SCHEMBL14562842 0.78 KCNH2 (0.40) KMT2AMEN1ALDH1A1KCNH2LMNA
SCHEMBL5546619 0.78 SMN1; SMN2 (0.43) GAAKMT2AMEN1SMN1; SMN2MAPT
SCHEMBL5544251 0.76 KDM4E (0.41) KMT2AMEN1TP53KDM4EALDH1A1
SCHEMBL14562825 0.74 KCNH2 (0.38) KCNH2LMNA
SCHEMBL6424126 0.74 KCNH2 (0.44) KMT2AALDH1A1KCNH2
SCHEMBL5546724 0.74 KCNH2 (0.44) SMN1; SMN2MAPTALDH1A1KCNH2LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2570418-A2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles compound OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2013-03-20 EP disclosed
EP-1555267-B1 2,3-DIHYDRO-6-NITROIMIDAZO[2,1-b]OXAZOLES OTSUKA PHARMA CO LTD (JP) 2013-01-16 EP disclosed
US-7262212-B2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2007-08-28 US disclosed
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2006-05-04 US disclosed
EP-1555267-A1 2,3-DIHYDRO-6-NITROIMIDAZO 2,1-b OXAZOLES OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2005-07-20 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles NR2C2, NR4A3, NR4A2 GAA 4165/4885KMT2A 4267/4885MEN1 3295/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.